Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
LAG-3 inhibitors and ligands target lymphocyte activation gene-3 (LAG-3), an inhibitory receptor on T cells. The gene was cloned in 1990 from activated lymphocytes, and its protein is closely related to the coreceptor cluster of differentiation 4 (CD4). Like CD4, LAG-3 binds major histocompatibility complex class II (MHC-II) molecules on antigen-presenting cells. A 2019 study identified fibrinogen-like protein 1 (FGL1), a liver-secreted protein, as a further major inhibitory ligand. LAG-3 is often coexpressed with programmed cell death protein 1 (PD-1) on exhausted T cells. Ieramilimab is an anti-LAG-3 antibody, and SA-15-P is a small molecule reported to block both the LAG-3/MHC-II and LAG-3/FGL1 interactions. LAG-3-IN-2 and LAG-3 degrader 1 extend the small-molecule tools for this checkpoint receptor.
LAG-3 biner 1 is a small molecule ligand that specifically targets the immune checkpoint lymphocyte activation gene 3 (LAG-3), exhibiting a Kd of 1.23 μM. This compound plays a significant role in modulating immune responses and is valuable for research applications focused on cancer diagnostics and the exploration of immune regulation involving LAG-3.
